Oak Hill Bio strengthens its leadership team with the appointment of Dr. Joerg Hipp as Chief Translational Science Officer to advance its rare disease pipeline and rugonersen development.
Oak Hill Bio announced the appointment of Joerg Hipp as Chief Translational Science Officer, a routine executive appointment with limited direct market impact.
Clinical-stage rare disease firm Oak Hill Bio has named Dr. Joerg Hipp as its new Chief Translational Science Officer. Dr. Hipp, who previously contributed to the development of the company's lead asset rugonersen, will oversee the firm's translational science and biomarker strategy.
Oak Hill Bio is a clinical-stage therapeutics company dedicated to developing treatments for rare diseases.
Dr. Hipp's appointment is expected to bolster the company's translational science capabilities, particularly regarding the development of its lead asset, rugonersen.